Immunohistochemical and ultrastructural characterization of brain tumors in S100β-v-erbB transgenic rats

Neuropathology

Volumn 28, Issue 6, 2008, Pages 591-598

  Yokoo, Hideaki ^a   Tanaka, Yuko ^a   Nobusawa, Sumihito ^a   Nakazato, Yoichi ^a   Ohgaki, Hiroko ^b  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Brain tumor; EGFR; Transgenic rats; v erbB

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PROTEIN S100B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX2.2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CELL DIFFERENTIATION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; GLIOMA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NONHUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; RAT; TRANSGENIC ANIMAL; TRANSGENIC RAT;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN NEOPLASMS; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOMA; HOMEODOMAIN PROTEINS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, ELECTRON; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEUROGLIA; OLIGODENDROGLIOMA; ONCOGENE PROTEINS V-ERBB; RATS; RATS, TRANSGENIC; S100 PROTEINS; TRANSCRIPTION FACTORS;

EID: 54849416143     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2008.00923.x     Document Type: Article

References (30)

1. Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004 64 : 6892 6899.
2. Rasheed BK, Wiltshire RN, Bigner SH, Bigner DD. Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 1999 11 : 162 167.
3. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 1998 4 : 148 158.
4. Schatzman RC, Evan GI, Privalsky ML, Bishop JM. Orientation of the v-erb-B gene product in the plasma membrane. Mol Cell Biol 1986 6 : 1329 1333.
5. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997 8 : 1197 1206.
6. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor- positive tumors: a new paradigm for cancer therapy. Cancer 2002 94 : 1593 1611.
7. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001 7 : 2958 2970.
8. Humphrey PA, Wong AJ, Vogelstein B et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 1990 87 : 4207 4211.
9. Cavenee WK. Genetics and new approaches to cancer therapy. Carcinogenesis 2002 23 : 683 686.
10. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 1992 89 : 4309 4313.
11. Schwechheimer K, Huang S, Cavenee WK. EGFR gene amplification - rearrangement in human glioblastomas. Int J Cancer 1995 62 : 145 148.
12. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005 353 : 2012 2024.
13. Weiss WA, Burns MJ, Hackett C et al. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 2003 63 : 1589 1595.
14. Ohgaki H, Kita D, Favereaux A et al. Brain tumors in S100beta-v-erbB transgenic rats. J Neuropathol Exp Neurol 2006 65 : 1111 1117.
15. Nakazato Y, Sasaki A, Hirato J, Ishida Y. Immunohistochemical localization of neurofilament protein in neuronal degenerations. Acta Neuropathol 1984 64 : 30 36.
16. Yokoo H, Nobusawa S, Takebayashi H et al. Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas. Am J Pathol 2004 164 : 1717 1725.
17. Yamaguchi H, Morimatsu M, Hirai S, Takahashi K. Alzheimer's neurofibrillary tangles are penetrated by astroglial processes and appear eosinophilic in their final stages. Acta Neuropathol 1987 72 : 214 217.
18. Sasaki A, Hirato J, Nakazato Y. Immunohistochemical study of microglia in the Creutzfeldt-Jakob diseased brain. Acta Neuropathol 1993 86 : 337 344.
19. Yokoo H, Sasaki A, Hirato J, Nakazato Y. A monoclonal antibody that specifically recognizes a novel mitochondrial protein of human astrocytes. J Neuropathol Exp Neurol 1996 55 : 716 721.
20. Sugawara K, Kurihara H, Negishi M et al. Nestin as a marker for proliferative endothelium in gliomas. Lab Invest 2002 82 : 345 351.
21. Tanaka Y, Yokoo H, Komori T et al. A distinct pattern of Olig2-positive cellular distribution in papillary glioneuronal tumors: a manifestation of the oligodendroglial phenotype? Acta Neuropathol 2005 110 : 39 47.
22. Rousseau A, Nutt CL, Betensky RA et al. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol 2006 65 : 1149 1156.
23. Ligon KL, Alberta JA, Kho AT et al. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol 2004 63 : 499 509.
24. Lu QR, Park JK, Noll E et al. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci USA 2001 98 : 10851 10856.
25. Marie Y, Sanson M, Mokhtari K et al. OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 2001 358 : 298 300.
26. World Health Organization. WHO Classification of Tumours of the Central Nervous System. Lyon : IARC, 2007.
27. Herschman HR, Levine L, de Vellis J. Appearance of a brain-specific antigen (S-100 protein) in the developing rat brain. J Neurochem 1971 18 : 629 633.
28. Kato K, Suzuki F, Morishita R, Asano T, Sato T. Selective increase in S-100 beta protein by aging in rat cerebral cortex. J Neurochem 1990 54 : 1269 1274.
29. Hachem S, Aguirre A, Vives V, Marks A, Gallo V, Legraverend C. Spatial and temporal expression of S100B in cells of oligodendrocyte lineage. Glia 2005 51 : 81 97.
30. Raponi E, Agenes F, Delphin C et al. S100B expression defines a state in which GFAP-expressing cells lose their neural stem cell potential and acquire a more mature developmental stage. Glia 2007 55 : 165 177.